South Korea Drug Pricing Strategies Needed Now, Says Merck KGaA's South Korean President Juergen Koenig

HONG KONG - South Korea needs to clarify drug pricing regulations and speed up its decision-making process for new products if it hopes to attract, or even maintain, investment in the R&D pharmaceutical space